Kadderum

Eltrombopag, the active ingredient in Kadderum, is a thrombopoietin receptor agonist presented as an oral tablet for oral use. It treats chronic immune thrombocytopenia, severe aplastic anemia, and hepatitis C‑associated thrombocytopenia by increasing platelet production. GNH USA supplies Kadderum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kadderum is a thrombopoietin receptor agonist used in disorders characterized by low platelet counts. - Chronic immune thrombocytopenia (ITP): raises platelet levels in patients with persistent immune‑mediated thrombocytopenia. - Severe aplastic anemia: supports hematopoiesis and increases platelet counts in bone‑marrow failure. - Hepatitis C‑associated thrombocytopenia: improves platelet numbers in patients with HCV‑related thrombocytopenia.

Kadderum may cause a range of adverse reactions.

Common Side Effects: - Nausea - Diarrhea - Fatigue - Headache

Serious or Rare Side Effects: - Thromboembolic events - Hepatotoxicity (elevated liver enzymes or severe liver injury) - Bone‑marrow fibrosis - Severe allergic reaction (anaphylaxis)

When prescribing Kadderum, clinicians should consider several safety measures. - Monitor liver function: check hepatic enzymes regularly. - Assess platelet counts: adjust therapy based on response. - Avoid in active thrombosis: contraindicated in patients with ongoing clotting disorders. - Use caution in hepatic impairment: dose may need adjustment. - Discontinue if severe liver injury occurs. - Store at below 25°C: keep in the original pack, protect from moisture.

Eltrombopag can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may markedly lower eltrombopag exposure. - Concurrent anticoagulants can raise the risk of thrombotic complications.

Moderate Interactions (Monitor Closely): - Co‑administration with other thrombopoietin receptor agonists may cause excessive platelet rise. - Hepatotoxic drugs (e.g., isoniazid) may exacerbate liver injury. - Antacids containing aluminum or magnesium can reduce oral absorption of eltrombopag.